Douglas Miehm
Stock Analyst at RBC Capital
(4.25)
# 1,492
Out of 5,152 analysts
423
Total ratings
53%
Success rate
6.4%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $19.77 → $19.86 | $10.86 | +82.92% | 2 | Nov 16, 2026 | |
| TSX: DR Medical Facilities Corporation | Maintained: Hold | $19.00 | $15.45 | +22.98% | 48 | Nov 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Maintained: Buy | $43.00 → $46.00 | $35.54 | +29.43% | 5 | Nov 13, 2026 | |
| TSX: WELL WELL Health Technologies Corp. | Maintained: Buy | $7.00 | $3.59 | +94.99% | 24 | Nov 11, 2026 | |
| MNKD MannKind | Reiterated: Hold | $4.75 → $5 | $4.23 | +18.20% | 11 | Nov 6, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Reiterated: Buy | $11.00 → $13.00 | $11.98 | +8.51% | 29 | Nov 6, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Reiterated: Buy | $22.00 | $19.49 | +12.88% | 44 | Nov 5, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $357 | $314.16 | +13.64% | 23 | Nov 1, 2026 | |
| AUPH Aurinia Pharmaceuticals | Rated: Hold | $16 → $18 | $16.30 | +10.43% | 45 | Oct 30, 2026 | |
| BLCO Bausch + Lomb | Rated: Buy | $21 → $23 | $21.37 | +7.63% | 40 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $12.70 → $14.11 | $11.78 | +19.81% | 106 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $25 → $37 | $36.49 | +0.03% | 7 | Oct 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.84 | $16.26 | -51.76% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.51 → $3.5 | $0.3818 | n/a | 30 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $19 | $2.65 | n/a | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 | €80.30 | n/a | 3 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $2.3 | $0.0001 | n/a | 2 | Nov 6, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $8.40 | n/a | 1 | Feb 5, 2009 |
Eupraxia Pharmaceuticals Inc.
Nov 16, 2026
Maintained: Buy
Price Target: $19.77 → $19.86
Current: $10.86
Upside: +82.92%
Medical Facilities Corporation
Nov 13, 2026
Maintained: Hold
Price Target: $19.00
Current: $15.45
Upside: +22.98%
Apotex Health Corp.
Nov 13, 2026
Maintained: Buy
Price Target: $43.00 → $46.00
Current: $35.54
Upside: +29.43%
WELL Health Technologies Corp.
Nov 11, 2026
Maintained: Buy
Price Target: $7.00
Current: $3.59
Upside: +94.99%
MannKind
Nov 6, 2026
Reiterated: Hold
Price Target: $4.75 → $5
Current: $4.23
Upside: +18.20%
Knight Therapeutics Inc.
Nov 6, 2026
Reiterated: Buy
Price Target: $11.00 → $13.00
Current: $11.98
Upside: +8.51%
DRI Healthcare Trust
Nov 5, 2026
Reiterated: Buy
Price Target: $22.00
Current: $19.49
Upside: +12.88%
Ligand Pharmaceuticals
Nov 1, 2026
Reiterated: Buy
Price Target: $357
Current: $314.16
Upside: +13.64%
Aurinia Pharmaceuticals
Oct 30, 2026
Rated: Hold
Price Target: $16 → $18
Current: $16.30
Upside: +10.43%
Bausch + Lomb
Oct 29, 2026
Rated: Buy
Price Target: $21 → $23
Current: $21.37
Upside: +7.63%
Oct 29, 2026
Reiterated: Hold
Price Target: $12.70 → $14.11
Current: $11.78
Upside: +19.81%
Oct 8, 2026
Rated: Hold
Price Target: $25 → $37
Current: $36.49
Upside: +0.03%
Mar 19, 2026
Reiterated: Buy
Price Target: $7.84
Current: $16.26
Upside: -51.76%
Nov 19, 2025
Reiterated: Buy
Price Target: $2.51 → $3.5
Current: $0.3818
Upside: n/a
Oct 8, 2021
Reiterated: Hold
Price Target: $18 → $19
Current: $2.65
Upside: n/a
Jun 23, 2021
Reiterated: Buy
Price Target: €22.00
Current: €80.30
Upside: n/a
Nov 6, 2013
Rated: Hold
Price Target: $3 → $2.3
Current: $0.0001
Upside: n/a
Feb 5, 2009
Upgraded: Buy
Price Target: n/a
Current: $8.40
Upside: n/a